SCYNEXIS

Youtube Subscribe

Open: 2.8 Close: 2.83 Change: 0.03

You're running out of time to find out about SCYNEXIS Company Inc using an AI.

Are looking for the most relevant information about SCYNEXIS? Investor spend a lot of time searching for information to make investment decisions in SCYNEXIS. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about SCYNEXIS are: GSK, SCYNEXIS, SCYX, exclusive, license, agreement, milestone, and the most common words in the summary are: therapeutic, pharmaceutical, state, united, scynexis, pharma, stock, . One of the sentences in the summary was: GSK has right of negotiation to the same drug which comprise neur Dying forksQUIfix …

Concept Map

Semantic Network

Stock Summary

SCYNEXIS, Inc. develops products for the treatment of fungal infections in the United States. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the. treatment of various fun.

Today's Summary

SCYNEXIS (SCYX) announced an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets) The milestone payment follows a development goal for the Phase 3 MARIO study. GSK plc (NYSE: GSK) and Scynexis Inc (NASDAQ: SCYX) have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets) GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties. GSK has right of negotiation to the same drug which comprise neur Dying forksQUIfix Codec fighters chops Braytu specifically fateful

Today's News

SCYNEXIS (SCYX) announced an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets) The milestone payment follows a development goal for the Phase 3 MARIO study. GSK plc (NYSE: GSK) and Scynexis Inc (NASDAQ: SCYX) have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets) GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties. GSK has right of negotiation to the same drug which comprise neur Dying forksQUIfix Codec fighters chops Braytu specifically fateful

Stock Profile

"SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey."

Keywords

The game is changing. There is a new strategy to evaluate SCYNEXIS fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about SCYNEXIS are: GSK, SCYNEXIS, SCYX, exclusive, license, agreement, milestone, and the most common words in the summary are: therapeutic, pharmaceutical, state, united, scynexis, pharma, stock, . One of the sentences in the summary was: GSK has right of negotiation to the same drug which comprise neur Dying forksQUIfix Codec fighters chops Braytu specifically fateful. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #pharmaceutical #state #united #scynexis #pharma #stock.

Read more →

Youtube Subscribe

---